JP3778366B2 - 細胞成長調節因子 - Google Patents
細胞成長調節因子 Download PDFInfo
- Publication number
- JP3778366B2 JP3778366B2 JP51109996A JP51109996A JP3778366B2 JP 3778366 B2 JP3778366 B2 JP 3778366B2 JP 51109996 A JP51109996 A JP 51109996A JP 51109996 A JP51109996 A JP 51109996A JP 3778366 B2 JP3778366 B2 JP 3778366B2
- Authority
- JP
- Japan
- Prior art keywords
- egr
- cells
- lmw
- cell
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000010261 cell growth Effects 0.000 title claims description 27
- 239000003630 growth substance Substances 0.000 title claims description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 127
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 65
- 230000012010 growth Effects 0.000 claims abstract description 49
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 44
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 239000000126 substance Substances 0.000 claims abstract description 26
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 26
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 25
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 22
- 230000035755 proliferation Effects 0.000 claims abstract description 22
- 210000000663 muscle cell Anatomy 0.000 claims abstract description 19
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 210000001124 body fluid Anatomy 0.000 claims abstract description 8
- 239000010839 body fluid Substances 0.000 claims abstract description 7
- 239000012530 fluid Substances 0.000 claims abstract description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 41
- 239000002953 phosphate buffered saline Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 34
- 238000004007 reversed phase HPLC Methods 0.000 claims description 24
- 210000000107 myocyte Anatomy 0.000 claims description 23
- 239000002609 medium Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 230000004614 tumor growth Effects 0.000 claims description 15
- 230000004663 cell proliferation Effects 0.000 claims description 12
- 230000004565 tumor cell growth Effects 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- 230000001885 phytohemagglutinin Effects 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 239000012979 RPMI medium Substances 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 5
- 210000004882 non-tumor cell Anatomy 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000002798 bone marrow cell Anatomy 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000012134 supernatant fraction Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000001143 conditioned effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 85
- 239000003636 conditioned culture medium Substances 0.000 description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- 239000003102 growth factor Substances 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 33
- 241000700159 Rattus Species 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 21
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 14
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 241001529936 Murinae Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 229940104230 thymidine Drugs 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 210000005087 mononuclear cell Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000012505 Superdex™ Substances 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 210000002948 striated muscle cell Anatomy 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000000540 fraction c Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- 108010059712 Pronase Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000002196 fr. b Anatomy 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical compound NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001672 cytoproliferative effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007811 spectroscopic assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Sorption Type Refrigeration Machines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11102194A IL111021A0 (en) | 1994-09-22 | 1994-09-22 | Factor derived from muscle cells |
| IL111021 | 1994-09-22 | ||
| PCT/US1995/012093 WO1996009060A1 (en) | 1994-09-22 | 1995-09-22 | Cell growth regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10509028A JPH10509028A (ja) | 1998-09-08 |
| JP3778366B2 true JP3778366B2 (ja) | 2006-05-24 |
Family
ID=11066570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51109996A Expired - Fee Related JP3778366B2 (ja) | 1994-09-22 | 1995-09-22 | 細胞成長調節因子 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5962331A (zh) |
| EP (1) | EP0782452B1 (zh) |
| JP (1) | JP3778366B2 (zh) |
| KR (1) | KR100392996B1 (zh) |
| CN (1) | CN1146432C (zh) |
| AT (1) | ATE214934T1 (zh) |
| AU (1) | AU692931B2 (zh) |
| BR (1) | BR9509154A (zh) |
| CA (1) | CA2198727C (zh) |
| DE (1) | DE69526096T2 (zh) |
| DK (1) | DK0782452T3 (zh) |
| ES (1) | ES2174963T3 (zh) |
| FI (1) | FI113153B (zh) |
| IL (2) | IL111021A0 (zh) |
| MX (1) | MX9702174A (zh) |
| RU (1) | RU2199327C2 (zh) |
| WO (1) | WO1996009060A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4328897A (en) * | 1996-08-23 | 1998-03-06 | Board Of Regents, The University Of Texas System | Anti-proliferative factor from transfected cells |
| IL131096A (en) * | 1999-07-26 | 2004-09-27 | Can Fite Technologies Ltd | Method for preparing a composition derived from muscle tissue |
| US20030143282A1 (en) * | 2002-01-28 | 2003-07-31 | Pnina Fishman | Adenosine A3 receptor agonist |
| PL2764351T3 (pl) * | 2011-09-29 | 2019-05-31 | Seattle Genetics Inc | Oznaczanie nienaruszonej masy związków środków sprzężonych z białkami |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708948A (en) * | 1984-04-20 | 1987-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Substantially purified tumor growth inhibitory factor |
| US5242692A (en) * | 1990-07-10 | 1993-09-07 | Bar Ilan University | Anti-metastatic factor |
-
1994
- 1994-09-22 IL IL11102194A patent/IL111021A0/xx unknown
-
1995
- 1995-09-21 US US08/531,783 patent/US5962331A/en not_active Expired - Fee Related
- 1995-09-22 MX MX9702174A patent/MX9702174A/es not_active IP Right Cessation
- 1995-09-22 ES ES95934498T patent/ES2174963T3/es not_active Expired - Lifetime
- 1995-09-22 EP EP95934498A patent/EP0782452B1/en not_active Expired - Lifetime
- 1995-09-22 CN CNB951963368A patent/CN1146432C/zh not_active Expired - Fee Related
- 1995-09-22 CA CA002198727A patent/CA2198727C/en not_active Expired - Fee Related
- 1995-09-22 RU RU97106333/13A patent/RU2199327C2/ru not_active IP Right Cessation
- 1995-09-22 BR BR9509154A patent/BR9509154A/pt not_active Application Discontinuation
- 1995-09-22 IL IL11541595A patent/IL115415A/en not_active IP Right Cessation
- 1995-09-22 KR KR1019970701853A patent/KR100392996B1/ko not_active IP Right Cessation
- 1995-09-22 AU AU36816/95A patent/AU692931B2/en not_active Ceased
- 1995-09-22 DK DK95934498T patent/DK0782452T3/da active
- 1995-09-22 DE DE69526096T patent/DE69526096T2/de not_active Expired - Fee Related
- 1995-09-22 WO PCT/US1995/012093 patent/WO1996009060A1/en active IP Right Grant
- 1995-09-22 JP JP51109996A patent/JP3778366B2/ja not_active Expired - Fee Related
- 1995-09-22 AT AT95934498T patent/ATE214934T1/de not_active IP Right Cessation
-
1997
- 1997-03-21 FI FI971190A patent/FI113153B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0782452B1 (en) | 2002-03-27 |
| RU2199327C2 (ru) | 2003-02-27 |
| CN1164190A (zh) | 1997-11-05 |
| DE69526096T2 (de) | 2002-09-26 |
| DE69526096D1 (de) | 2002-05-02 |
| FI971190A (fi) | 1997-03-21 |
| IL111021A0 (en) | 1994-11-28 |
| US5962331A (en) | 1999-10-05 |
| AU692931B2 (en) | 1998-06-18 |
| CN1146432C (zh) | 2004-04-21 |
| FI113153B (fi) | 2004-03-15 |
| AU3681695A (en) | 1996-04-09 |
| CA2198727A1 (en) | 1996-03-28 |
| DK0782452T3 (da) | 2002-07-01 |
| ES2174963T3 (es) | 2002-11-16 |
| ATE214934T1 (de) | 2002-04-15 |
| IL115415A0 (en) | 1995-12-31 |
| EP0782452A1 (en) | 1997-07-09 |
| JPH10509028A (ja) | 1998-09-08 |
| FI971190A0 (fi) | 1997-03-21 |
| WO1996009060A1 (en) | 1996-03-28 |
| IL115415A (en) | 2001-05-20 |
| CA2198727C (en) | 2007-03-27 |
| MX9702174A (es) | 1998-04-30 |
| KR100392996B1 (ko) | 2003-11-28 |
| BR9509154A (pt) | 1997-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tagliabue et al. | Natural cytotoxicity of mouse monocytes and macrophages | |
| DE69131255T2 (de) | Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten | |
| JP2506340B2 (ja) | 医薬組成物 | |
| DE4244715C2 (de) | Verfahren zur Herstellung individuum-spezifischer, gegen Tumorantigene gerichtete monoklonale Antikörper | |
| JPH04502143A (ja) | 癌診断および管理における自己分泌運動性因子 | |
| JPH0780764B2 (ja) | 新生物形成病用医薬組成物 | |
| JP3778366B2 (ja) | 細胞成長調節因子 | |
| Roberts et al. | Influence of cortisone on free hydroxyproline in the developing chick embryo | |
| US4046877A (en) | Method of increasing immunologic competence | |
| Price et al. | Heterogeneity of molecules with low molecular weight isolated from media conditioned by human leukocytes and capable of stimulating colony formation by human granulopoietic progenitor cells | |
| JP2002519303A (ja) | 脂質動員性を有する糖タンパク質およびその治療的適用 | |
| Clavio et al. | Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients | |
| MXPA97002174A (en) | Celu growth regulator | |
| JP2001502533A (ja) | ママスタチンのヌクレオチドおよびタンパク質配列およびその使用法 | |
| Miyakoshi et al. | Acting mechanisms of Lentinan in human—I. augmentation of DNA synthesis and immunoglobulin production of peripheral mononuclear cells | |
| EP0145775B1 (en) | A METHOD OF TREATING INTERFERON SENSITIVE DISEASES, AND A METHOD AND A DEVICE FOR PREPARING A $g(g)-INTERFERON CONTAINING PREPARATION | |
| JP2954248B2 (ja) | ナトリウム排泄増加ホルモン | |
| EP0681480B1 (en) | Recognin vaccines | |
| Smith | Recent work on vitamin B12 | |
| DE68911305T2 (de) | Das lungenwachstum stimulierende und hemmende faktoren für krebstumorzellen. | |
| US4929443A (en) | Method of treating interferon sensitive diseases, and a method and device for preparing γ-interferon containing preparation | |
| EL | Isolation and chemistry of vitamin B12. | |
| JPS59501786A (ja) | 免疫刺戟体 | |
| Spatafora et al. | Tumor necrosis factor release by pulmonary alveolar macrophages | |
| Konwalinka et al. | A case of acquired pure red cell anemia studied by cloning of erythroid progenitor cells in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040406 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040323 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040706 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040818 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051107 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051221 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060223 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |